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Background: Rheumatoid arthritis (RA) is an autoimmune disease with no known cure 
that affects approximately 1.3 million Americans. RA patients suffer from chronic pain 
and inflammation and are faced with probable disability, reduced life expectancy, and 
increased risk of several other diseases. In the last decade, biological therapies have 
revolutionized RA treatment. Although administration of a tumor necrosis factor (TNF) 
neutralizing agent is the first-line biological therapy, many RA patients show only partial 
or no clinical response to treatment. Subsequently, anti-B cell, anti-T cell, or anti-IL6 
therapies can be evaluated. Streamlining of treatment protocols is necessary to improve 
patient outcomes. 
Methods: Serum was collected from 23 active, seropositive RA patients on concomitant 
methotrexate, at baseline and six months after treatment with rituximab. Based on the 
American College of Rheumatology improvement criteria, at a level of 20% (ACR20), 
patients were categorized as either responders or non-responders. An untargeted 
metabolomics approach was used to characterize the serum metabolome of patients. High 
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resolution one-dimensional 1H-NMR spectra were acquired using a Bruker Avance 700 
MHz spectrometer. In addition, A Thermo Scientific Q Exactive Hybrid Quadrupole-
Orbitrap mass spectrometer was used for UPLC-MS/MS of serum lipids. Data processing, 
statistical analysis, and pathway mapping were performed in MATLAB in conjunction 
with several metabolomics software packages including, NMRLab, MetaboLab, Chenomx, 
MetaboAnalyst, MetaboSearch, VANTED, Xcalibur, and Sieve. 
Results: Based on the ACR20 criteria, at baseline, 14 patients were characterized as 
responders and 9 patients were considered non-responders. Similarly, 20 patients followed-
up at six months, 13 responders and 7 non-responders. Seven polar metabolites and 15 
unique lipid species achieved a p-value of less than 0.05 for a two sample t-test prior to 
treatment with rituximab. Following rituximab therapy, five polar metabolites and 37 lipid 
species were statistically significant between groups. Pathway analysis of both polar and 
apolar metabolites revealed metabolic differences between responder and non-responders 
before and after treatment with rituximab. 
Conclusion: A clear relationship between blood metabolic profiles and clinical response 
to rituximab therapy suggests that 1H-NMR and UPLC-MS/MS are promising tools for RA 
therapy optimization and acceleration of treatment protocols to improve patient outcomes. 
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I. Introduction 
Rheumatoid arthritis (RA) is a common autoimmune disease that affects approximately 
1.3 million Americans (1) and an estimated 0.5 - 1% of the global population (2, 3). 
Invasion of immune cells and characteristic chronic inflammation lead to painful cartilage 
and joint destruction and poor long term outcomes (3, 4). RA patients suffer from probable 
disability, diminished life expectancy, and increased risk of other diseases (2, 4, 5). Greater 
understanding of the pathogenesis of RA has transformed the therapeutic options available 
to people afflicted with the disease (4). Therapy for RA was revolutionized a decade or so 
ago by the introduction of biological agents, especially agents that target the inflammatory 
cytokine tumor necrosis factor (TNF) (2). Current treatment protocols typically involve 
sequentially evaluating biological therapy options until an acceptable level of disease 
control is achieved. The initial, first-line therapy involves a TNF neutralizing treatment, 
such as infliximab (6). However, a significant number of patients exhibit only partial or no 
therapeutic response to anti-TNF treatments (4, 7-9). Following anti-TNF failure, patients 
may be treated with anti-B cell (rituximab), anti-T cell (abatacept), or anti-IL6 
(tocilizumab) therapy. 
Early detection and initiation of an effective treatment are critical for minimizing 
damage caused by the disease, improving immediate and long-term patient outcomes, and 
quality of life (10). Aggressive treatment is paramount if the damage caused by RA is to 
be controlled (4). In particular, successful disease management requires better tools for 
diagnosis and streamlining of treatment protocols (9, 10). Thus, choosing and initiating the 
right biological treatment earlier in the course of the disease could help to reach the goal 
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of remission. A greater effort should be made to develop the tools necessary to employ a 
personalized medicine approach, in an attempt to match patients with the most appropriate 
therapy option for their disease subtype.  
Given the complexity and heterogeneity of RA, it seems doubtful that a single cytokine 
or biomarker will be sufficient for therapy discrimination. Instead, biomarker signatures 
may represent more realistic approach to personalized therapeutic protocols for those 
suffering from the disease (11). Once genetic and epigenetic risk factors and environmental 
triggers have led from preclinical to clinical disease, RA may be driven by several different 
factors. These factors include cytokines such as TNF or IL-6, or different cell subset, such 
as B-cell, T-cell or macrophages, which ultimately lead to a perpetuating cycle of chronic 
synovitis (4). Identifying these unique signatures could make a significant difference in RA 
management and attainment of disease remission. 
Variations in metabolite concentrations can also serve as diagnostic or prognostic 
biomarkers. We propose that the study of metabolomics in inflammatory diseases can be 
useful to identify biomarker signatures. Metabolomics is the science of identifying and 
quantifying the biochemical byproducts of cellular metabolism, frequently referred to as 
metabolites. The goal of metabolomics is to comprehensively measure the small molecules 
present in a specific cell, tissue, organ, organism, or biofluid (12, 13). Metabolomics has 
many applications and is frequently used to identify single biomarkers, classify metabolite 
patterns of health or disease, elucidate pathways involved in pathogenesis, uncover novel 
targets for modulation of dysregulated pathways, and to monitor treatment and/or disease 
status (13, 14). Recent studies in other fields, such as oncology, demonstrate the 
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applicability of metabolomics using serum and urine samples for diagnosis and prognosis. 
The application of metabolomics to the field of cancer research has demonstrated that 
nuclear magnetic resonance spectroscopy (NMR) and mass spectrometry (MS) can be 
useful tools for characterizing the metabolic dysregulation that is a signature of the 
complex and heterogeneous disease (15-20). Similar to cancer, RA is a complex and 
heterogeneous disease that requires a personalized approach to treatment. However, little 
is known about the metabolome in RA and how it can be used for diagnosis and treatment 
evaluation. 
The application of metabolomics to RA is still in its infancy, but early studies have 
yielded promising results. One study published in 2011 found that serum metabolites 
detected by MS successfully distinguished metabolic profiles of individuals with RA, 
psoriatic arthritis (PsoA), and heathy controls and concluded that serum metabolite 
profiling could be a useful diagnostic tool. Specifically, they found elevated levels of 
glyceric acid, D-ribofuranose, and hypoxanthine, while histidine, threonic acid, 
methionine, cholesterol, asparagine, and threonine were lower in RA patients compared to 
healthy controls (21). Another study assessed synovial fluid metabolite profiles with MS 
and found 20 potential biomarkers for differentiating RA from other types of inflammatory 
arthritis. Notably, citrulline, succinate, glutamine, octadecanol, isopalmitic acid, and 
glycerol were identified (22). Similarly, a lipidomics analysis of synovial fluid 
demonstrated that lipid profiles are dependent upon both disease type (osteoarthritis (OA) 
or RA) and stage (early or late OA). The researchers proposed that these changes may be 
the result of compensatory lubrication mechanisms and/or related to inflammation and may 
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be disease and stage of progression specific signatures (23). These studies suggest that 
metabolomics analyses of several different biological fluids may be useful diagnostic tools 
prior to initiation of treatment and may also prove effective for earlier detection of RA. In 
addition, an NMR analysis of baseline urine metabolomes successfully discriminated RA 
patients based on their response to anti-TNF therapy. Specifically, histamine, glutamine, 
xanthurenic acid, and ethanolamine were detected in RA patient urine and significantly 
contributed to differences between response groups (9). These findings indicate that 
metabolic profiling has the potential to effectively predict patient response to therapy prior 
to administration. Here we show that an untargeted analysis of polar and lipid metabolites 
from serum samples by 1D 1H-NMR and UPLC-MS/MS is a promising clinical tool for 




The ARISE (Assessment of Rituximab’s Immunomodulatory Synovial Effects 
registered at ClinicalTrials.Gov NCT00147966) clinical trial was recently described in 
detail (8). Briefly, the study enrolled persons between the ages of 18–70 years with an 
established diagnosis of RA and a positive serum test for rheumatoid factor (RF). Patients 
were required to have active disease (defined as a tender joint count ≥8/68, a swollen joint 
count ≥6/66, and either early morning stiffness ≥45 min in duration or an elevation in 
erythrocyte sedimentation rate (ESR) ≥28 mm/h or C-reactive protein (CRP) ≥1.5 mg/dl), 
despite the concomitant use of methotrexate (MTX) at a dose of ≥12.5 mg/week for at least 
12 weeks. Concomitant use of non-steroidal anti-inflammatory drugs and oral prednisone 
at doses of 10 mg/day or less were permitted, provided dosing was stable for at least 4 
weeks before the study. Patients previously treated with tumor necrosis factor (TNF) 
inhibitors were permitted to enroll in the study provided they had been off therapy for ≥2 
months for etanercept and ≥3 months for adalimumab or infliximab. Exclusion criteria 
included prior treatment with rituximab, active or recent infections, pre-existing 
malignancy, and a history of infection with HIV or hepatitis B or C. Patients received 1 g 
rituximab intravenously on day 0, and again on day 14, in the absence of peri-infusion 
steroids. Blood was collected on day 0, and at 2 and 6 months following treatment. Of 23 
enrolled patients, 20 patients completed the 6-month protocol and are included in the serum 
analysis. Local Institutional Review Board (University of California at San Diego 
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Institutional Review Board) approval was obtained, and all patients signed written 
informed consent before study entry (8). 
 
Clinical Outcomes 
The primary clinical outcome was response according to the American College of 
Rheumatology (ACR) improvement criteria, at a 20% level (ACR20), at 6 months (8). 
Secondary clinical outcomes included ACR20, as well as, ACR50 and ACR70 responses 
at monthly time points, Disease Activity Score using a 28 joint count (DAS28) (24), and 
changes in individual disease activity parameters: tender joint count, swollen joint count, 
physician global assessment of disease, patient global assessment of disease, patient 
assessment of pain, measure of functional status using the Health Assessment 
Questionnaire (HAQ), and CRP and ESR at monthly time points. 
 
Metabolomics Sample Preparation 
Frozen human serum samples were provided by Dr. Monica Guma from the Division of 
Rheumatology, Allergy, and Immunology at the University of San Diego, School of 
Medicine (La Jolla, CA). Samples were de-identified, shipped on dry ice, and stored at -
80C prior to analysis. Lipid and protein fractions were removed via ultrafiltration 
(Nanosep 3K OMEGA, Pall Corporation, Ann Arbor, MI) at 4C (25). A 160 µL aliquot 
of filtered biofluid was used for NMR analysis. The biofluid was combined with 20 µL of 
D2O and 20 µL of phosphate buffer containing TMSP-d4 and sodium azide (final 
concentrations 100 mM, 0.1 mM, and 0.05% (w/v) respectively). Samples were centrifuged 
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at maximum speed for 10 minutes at 4C to remove any insoluble particulates and a 180 
L aliquot of each prepared sample was transferred to a 3 mm NMR tube (Norell, 
Landisville, NJ) prior to data acquisition. 
The apolar metabolites were recovered from the filter with two successive washes with 
250 L of 0.9% saline (20). Samples were spiked with the following stable isotopically 
labeled internal standards: 1,2-dipalmitoyl-d62-sn-glycero-3-phosphoethanolamine (16:0 
PE-d62), 1,2-dimyristoyl-d54-sn-glycero-2-[phospho-L-serine] sodium salt (14:0 PS-d54), 
1,2-dilauroyl-sn-glycero-2-phosphocholine (12:0 PC), 1,2-dioleoyl-sn-glycero-3-
phosphoinositol ammonium salt (18:1 PI), Ceramide/Sphingoid Internal Standard Mixture 
I (Avanti Polar Lipids Inc., Alabaster, Alabama), and heptadecanoic-17,17,17-d3 acid 
(CDN Isotopes, Pointe-Claire, Quebec, Canada). Recovered lipids were isolated via 
extraction by adding the 500 L saline solution to 500 L methanol and 1 mL chloroform 
in a glass vial. Individual samples were vortexed immediately to ensure protein 
denaturation. Subsequently, samples were agitated on a platform shaker (Heidolph, Elk 
Grove Village, IL) for 10 minutes at 2500 rpm. Phase separation was achieved by 
centrifugation at 4750 rpm for 20 minutes at 4C. For each sample, 200 L aliquot of the 
lipid containing chloroform phase was transferred into glass tube. Aliquots were dried at -
4C with a CentriVap Concentrator (Labconco, Kansas City, MO). Dried lipids were 
resuspended in 200 L of 65:30:5 acetonitrile:isopropanol:water and transferred into glass 




Nuclear Magnetic Resonance Spectroscopy Acquisition and Data Processing 
A 16.4 T (700MHz) Bruker Avance spectrometer equipped with a 5 mm TCI 
cryogenically cooled probe and autosampler (Bruker BioSpin Corp., Billerica, MA) was 
used to acquire spectra. Samples were permitted to equilibrate in the magnet prior to 
acquisition. A one dimensional 1H-NMR pulse sequence with excitation sculpting water 
suppression was used for data acquisition (26). Spectra were processed with NMRLab and 
MetaboLab (27) in the MATLAB programming environment (MathWorks Inc., Natick, 
MA). Metabolite concentrations were normalized to the TMSP-d4 peak. Post-processing 
for statistical purposes included alignment, scaling, exclusion of the regions containing the 
water and TMSP peaks, and generalized log transformations (28). Metabolite assignment 
and quantification was performed using Chenomx NMR Suite (Chenomx Inc., Edmonton, 
Alberta, Canada), the Birmingham Metabolite Library (29), and the Human Metabolome 
Database (30). 
 
Mass Spectrometry Acquisition and Data Processing 
A Q Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer equipped with an Accela 
1250 pump and autosampler (Thermo Scientific, Waltham, MA) was used for UPLC-
MS/MS analysis of the serum lipid fractions. Separation was achieved on a Kinetex 2.6 
µm C-18 100 Å column (Phenomenex, Torrance, CA). Mobile phase A was an 80:20 
solution of water and acetonitrile containing 10 mM ammonium acetate and 0.05% (w/v) 
formic acid. Mobile phase B was a solution of 90:9:1 isopropanol:acetonitrile:water with 
10 mM ammonium acetate and 0.05% (w/v) formic acid. The chromatography gradient 
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began with 90% mobile phase A, decreasing to 5% mobile phase A over 20 minutes, 
holding at 5% mobile phase A for an additional 7 minutes, and then gradually increasing 
back to 90% mobile phase A over 8 minutes to re-equilibrate the column prior to injection 
of the subsequent sample. The total chromatography run time was 35 minutes at a flow rate 
of 0.3 mL/min. The UPLC system was coupled to the spectrometer with an electrospray 
ionization source (ESI) and spectra were recorded in both negative and positive ionization 
modes for maximal metabolite coverage. For negative ionization mode, the spray voltage 
and capillary temperature were set at 3.0 kV and 300C, respectively. For positive 
ionization mode, the spray voltage was adjusted to 2.5 kV and the capillary temperature 
was decreased to 275C. For both acquisition modes, the sheath and auxiliary gas flow 
rates were set to 45 and 11 units, respectively. Solvent blanks and pooled quality controls 
were injected periodically to monitor column carry over and instrument stability. 
Data acquisition was performed using the Thermo Scientific software package Xcalibur 
and then further imported into Sieve Software 2.1 (Thermo Scientific) for processing.  The 
features obtained in Sieve were then imported and analyzed in MATLAB. Spectra 
deconvolution were processed according to mass accuracy and retention time. Metabolite 
assignment was done at  a 5 ppm mass accuracy range by interrogation of several databases 
including KEGG (31), LIPID MAPS (32), Human Metabolome Database (HMDB) (30), 
Madison Metabolomics Consortium Database (MMCD) (33), and Metlin (34), in part using 
MetaboSearch (35), a software tool developed for untargeted MS-based metabolomics. 
Intensities were normalized to internal standards that were present in all samples. For 
negative ionization mode, heptadecanoic-17,17,17-d3 was used. (2S,3R)-2-
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aminoheptadecane-1,3-diol (Sphinganine C17) was used for normalization of intensities 
generated in positive ionization mode. Following normalization, metabolites identified in 
each mode were merged to generate a composite list of metabolites prior to statistical 
analysis in MATLAB. Where accurate masses and retention times were associated with 
multiple lipid classes, MS/MS analysis was performed to fragment the molecules of interest 
to improve assignment confidence. 
  
Statistical Analysis 
For individual metabolites, statistical significance was evaluated using a two-sample t-
test (statistical significance: *p<0.10, **p<0.05, and ***p<0.01). Multivariate analysis was 
performed using PLS-Toolbox (Eigenvector Research, Manson, WA) in the MATLAB 
programming environment. Supervised partial least squares discriminant analysis 
(PLSDA) was used to evaluate global differences between responders and non-responders 
before and after treatment with rituximab. Polar metabolite correlation relationships were 
reported as Pearson’s correlation coefficients and visualized as a heat map and hierarchical 
clustering analysis with Euclidean distance metric in MATLAB. 
 
Pathway Analysis 
MetaboAnalyst 3.0 (http://www.metaboanalyst.ca/) was used identify pathways of 
significant interest involving polar metabolites (36, 37). In addition, VANTED 
(http://vanted.ipk-gatersleben.de/) software was used for pathway analysis of statistically 
significant lipid classes (38). The upregulation or downregulation of individual lipid 
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species was evaluated by calculating the fold change between responders and non-
responders. A global test algorithm was applied to determine the overall significance of 
each pathway between the two groups (39). Relative abundances are reported as colors to 
indicate the direction of statistically significant differences between groups. Polar and 
apolar pathways were manually integrated to provide a more comprehensive picture of the 
overall metabolic dysregulation found in rheumatoid arthritis patients relative to response 
to rituximab therapy. 
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III. Results 
Patient Response to Rituximab Therapy 
Following treatment, patients were categorized as either rituximab responders or non-
responders as determined by ACR criteria. Patients who attained a 20% (ACR20) or greater 
improvement in their disease were classified as responders (8). At baseline, 14 patients 
were classified as responders and the remaining 9 patients were considered non-responders 
(Table 1). Similarly, of the 20 patients who follow-up at six months, 13 were in the 
responder group and the remaining 7 were in the non-responder group. 
 
Metabolomics Approach to Data Collection and Analysis 
An unbiased, untargeted metabolomics technique was applied to both MS and NMR 
experiments. Polar and apolar fractions were prepared for all 43 samples. The polar 
fractions were analyzed by 1D 1H-NMR, while lipids were analyzed by UPLC-MS/MS. 
Using multiple databases, a total of 48 metabolites were identified and quantified from the 
NMR spectra (29, 30). Polar metabolites were predominantly amino acids, ketone bodies, 
and intermediates of energy metabolism. A complete list of polar metabolites, mean 
concentrations and standard deviations, and reference values are listed in Table 2. While 
several metabolite concentrations detected were abnormal, many were within previously 
measured normal ranges, indicating that a single metabolite biomarker is unlikely for RA, 
but a disease specific profile signature is still possible. Including internal standards, 
interrogation of several reference libraries yielded 584 identifiable unique lipid compounds 
from the apolar fraction (30-35). Several major classes of lipids were well represented 
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including: phosphatidic acids (PA), phosphatidylcholines (PC), 
phosphatidylethanolamines (PE), phosphatidylglycerols (PG), phosphatidylinositols (PI), 
phosphatidylserines (PS), sphingomyelins (SM), ceramides (Cer), sterols, triglycerides 
(TG), and free fatty acids. In addition to standard ester linkage glycerophospholipids, alkyl 
ether and alkenyl ether linkages were also detected, as indicated by an O- or P- prefix, 
respectively. Lipid species that were statistically significant between responders and non-
responders before and after treatment can be found in Table 3 and Table 4, respectively. 
Following normalization, UPLC-MS and 1H-NMR data sets were scaled and combined for 
multivariate statistical analysis. 
 
Differences in Metabolite Profiles Before Treatment  
Polar metabolite profiles of patient sera before rituximab therapy was accomplished 
using 1D 1H-NMR spectroscopy. Mean spectra for responders and non-responders before 
rituximab administration are shown in Figure 1a. Fitting of the 1H-NMR spectra revealed 
13 polar metabolites that achieved a p-value less than 0.10 when a two sample t-test was 
performed. Seven of these metabolites, phenylalanine, 2-hydroxyvalerate, succinate, 
choline, glycine, acetoacetate, and tyrosine, achieved a p-value of less than 0.05 (Figure 
2a). Interestingly, all of the significant metabolites were lower in responders relative to 
non-responders. Mean spectra (Figure 1a) show that most, but not all, features are 
diminished in responders. Unexpectedly, Pearson’s correlation coefficients show that the 
relationships between polar metabolites are all positive. Not surprisingly, metabolites 
primarily cluster into groups according to their biological function or chemical 
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classification. For example ketone bodies, branched chain amino acids, and aromatic amino 
acids form close associations on the heat map (Figure 3). 
Apolar metabolites were isolated by UPLC-MS/MS in both negative and positive modes 
for the most complete lipidome coverage. Thousands of features were detected in the MS 
spectra. Of which, 584 were matched to known compounds reported in a number of 
established libraries. A two sample t-test resulted in 41 compounds with a p-value of less 
than 0.10. Of these lipids, 15 achieved p-values of less than 0.05 (Table 3). Of the 
statistically different lipids, 80% (12/15) are glycerophospholipids, suggesting that 
metabolism and/or regulation of these lipids is an important difference between groups. 
Lipid species that were identified as statistically significant were grouped according to their 
classes. Fold-changes were calculated between responders and non-responders (data not 
shown). This revealed interesting trends amongst lipid species. Relative to non-responders, 
responders displayed elevated levels of phosphatidylinositols, phosphatidylcholines, and 
alkyl/alkenyl ether phosphatidylethanolamines. In contrast, phosphatidylglycerols and 
phosphatidylserines were lower in responders than non-responders for both ester and ether 
linked fatty acid chains (Table 5). 
 
Differences in Metabolite Profiles Following Treatment  
Patient clinical parameters were assessed periodically over six months following 
rituximab therapy. Serum collected at the six month follow-up was used for metabolomics 
analysis. Mean 1D 1H-NMR spectra at six months (Figure 1b) show clear differences 
between time points that are indicative of differential metabolic response to rituximab, as 
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well as, the effects of rituximab on both populations despite clinical parameters. Polar 
metabolite quantification from 1D 1H-NMR spectra six months following rituximab 
therapy revealed 7 polar metabolites that attained a p-value of less than 0.10 between 
responders and non-responders. Five of these metabolites, succinate, taurine, lactate, 
pyruvate, and aspartate achieved a p-value of less than 0.05 (Figure 2b).  
Following rituximab therapy, the composite UPLC-MS analysis of the apolar fraction 
of patient sera resulted in the identification of 69 lipid unique species that achieved a p-
value of less than 0.10. Of these, 37 metabolites resulted in a p-value of less than 0.05 when 
comparing responders to non-responders (Table 4). Similar to the baseline data, many of 
these lipid species belong to the glycerophospholipid class (24/37 or 65%). Again, 
significant lipids were clustered into classes to identify trends. Relative fold-changes were 
calculated for lipid species that were significant between responders and non-responders 
(data not shown). Six months after treatment with rituximab, elevated levels of 
phosphatidic acids, phosphatidylcholines, phosphatidylserines, and alkyl/alkenyl ether 
phosphatidylglycerols were observed in responders relative to non-responders. Conversely, 
phosphatidylethanolamines, phosphatidylinositols, alkyl/alkenyl ether-
phosphatidylcholines, and alkyl/alkenyl ether phosphatidylserines were lower in 
responders than non-responders (Table 5). Taken together, these trends suggest changes in 




Multivariate Analysis of Identified Metabolites Differentiates Responders and Non-
responders 
Polar and apolar data sets were scaled and combined to capture the relative contribution 
of each metabolite to the overall differences observed between responders and non-
responders. PLS-Toolbox was used to perform partial least squares discriminant analysis 
(PLSDA) of all identified metabolites before and after rituximab treatment. At both time 
points, PLSDA successfully separated responders and non-responders (Figure 4). PLSDA 
of the pre- and post-treatment metabolites shows a similar degree of separation, particularly 
with respect to latent variable 1 (LV1). However, separation is largely diminished in 
regards to latent variable 2 (LV2), reflecting the observed shifts in the metabolite profiles 
of both groups over time. The decrease in separation may be a signature of the metabolic 
shifts that are a result of the observed B cell ablation that occurs with rituximab 
administration independent of clinical response (8). Despite the relatively small latent 
variables, both PLSDA scores plots show clear separation between groups, particularly in 
the x-direction. The R2 values for pre- and post-treatment analyses were 0.905234 and 
0.968213, respectively. 
 
Pathway Analysis Indicates Several Metabolic Pathway Differences Between Groups 
Detected polar metabolites were mapped to known metabolic pathways using 
MetaboAnalyst 3.0 (36, 37). Pathways were ranked by their overall p-values. Pathways 
that had a statistically significant overall p-value and contained a large number of 
metabolite hits relative to the total number of metabolites were of particular interest. In 
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addition, VANTED software (38) was used to construct a metabolic pathway for the 
glycerophospholipids which represents the majority of the statistically significant apolar 
metabolites identified before and after rituximab therapy (≥65% for both). Mixed polar and 
apolar pathway analysis tools are not currently available, so pathway analyses were 
performed independently and combined to give the most comprehensive picture of the 
differences in metabolism between rituximab responders and non-responders (Figure 5). 
Pathway analyses were also performed at both time points to reflect metabolic changes 
initiated by rituximab therapy. Prior to treatment, several classes of glycerophospholipids 
were downregulated in responders relative to non-responders. Similarly, the polar 
metabolites related to these pathways were also lower in responders. Downregulation of 
the glycine, serine, and threonine pathway, which is connected to 
phosphatidylethanolamine and phosphatidylserine metabolism, is consistent with the 
observed relative intensities of these phospholipid classes in responders. Furthermore, 
choline, an essential building block for phosphatidylcholines, was reduced in responders, 
which is consistent with the relative downregulation of the ether linked 
phosphatidylcholines detected by UPLC-MS. Free glycerol was also lower in responders 
when compared to non-responders, which is also indicative of significant differences in 
glycerophospholipid metabolism between responders and non-responders prior to 
treatment. Taken together, these data indicate that the global metabolite signatures of 
responders and non-responders are distinct before treatment with rituximab. 
In many cases, treatment with rituximab either ablated or reversed the trends observed 
before treatment. The previously detected differences in the glycine, serine, and threonine 
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metabolic pathway, as well as, glycerol and choline were not observed after treatment. 
Instead, changes in pyruvate metabolism and TCA cycle intermediates, namely lactate, 
pyruvate, fumarate, citrate, and succinate, contributed more significantly to differences 
seen between the groups following rituximab therapy. Changes in apolar metabolites 
involved in the glycerophospholipid pathway were consistent with their polar counterparts. 
Interestingly, after treatment there are unique trends between standard ester and 
alkyl/alkenyl ether linkage species for all major classes of phospholipids. In fact, in many 
cases, opposite trends were observed between linkage types for the same class of 
phospholipid. These differences clearly demonstrate that global metabolite signatures of 
responders and non-responders are distinctive following treatment with rituximab. 
 
Global Effects of Rituximab Treatment Independent of Patient Response 
When responders and non-responders were analyzed separately to compare baseline to 
six month follow-up, 13 polar (Table 6) and 23 apolar statistically significant metabolites 
were shared by both groups. Regardless of clinical response (responders vs. non-
responders), rituximab is effective at ablating circulating B-cells (8). Common metabolic 
shifts between groups are therefore likely to be indicative of changes that are secondary to 
B-cell ablation. Pathway analysis of these metabolites were performed in MetaboAnalyst 
and VANTED, and manually combined. The resulting composite pathway indicates several 
similarities between responders (Figure 6a) and non-responders (Figure 6b). Before 
treatment, almost all glycerophospholipids and their related polar compounds are 
downregulated or not statistically significant regardless of clinical response. These include 
 19 
phosphatidic acids, phosphatidylinositols, phosphatidylserines, phosphatidylcholines, 
choline, and phosphatidylethanolamines. Only phosphatidylglycerols were observed to be 
lower after rituximab treatment. Not surprisingly, more changes were observed in 
responders which may be a clue to understanding the observed differences in clinically 
relevant parameters. Overall, these data show that responders and non-responders have 
unique metabolic signatures before and after treatment with rituximab. In addition, 
rituximab therapy observably alters metabolic activity and profile signatures regardless of 
clinical response. 
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Figure 1. Mean 1D 1H-NMR spectra of responders and non-responders before (a) 
and 6 months after (b) rituximab therapy. Variations in spectral intensities indicate 









Figure 2. Significant polar metabolite concentrations in rituximab responders and 
non-responders. Mean concentrations ( SD) of sera polar metabolites in RA patients 
measured by 1H-NMR before (a) and after (b) treatment with rituximab (Lactate excluded 
due to scale). *p<0.1 **p<0.05 
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Figure 3. Heat map and hierarchical cluster analysis of polar metabolites identified 





Figure 4. Partial least squares discriminant analysis of metabolites identified by 1D 
1H-NMR and UPLC-MS/MS in sera from rheumatoid arthritis patients. Scores plot 
obtained from samples collected before (a) and after (b) treatment with rituximab 







Figure 5. Pathway analysis of significant metabolite identified in RA patient sera 
before (a) and after (b) treatment with rituximab. Blue indicates classes that are 
downregulated in responders, red indicates classes that are upregulated in responders, 
yellow is no significant difference, and light blue indicates not detected. Split boxes 







Figure 6. Pathway analysis indicating global effects of rituximab treatment in 
responders (a) and non-responders (b). Blue indicates classes that are downregulated 
after treatment, red indicates classes that are upregulated after treatment, yellow is no 
significant difference, and light blue indicates not detected. Split boxes represent ester 






Table 1. Baseline characteristics of rheumatoid arthritis patients by response to 
rituximab at 6 months. MTX: Methotrexate, DAS28: 28 joint disease activity score, 
ESR: Erythrocyte sedimentation rate, HAQ: Health assessment questionnaire, CCP: 
Cyclic citrullinated peptide, ACR: American College of Rheumatology 
Clinical Parameter Responders (n = 14) Non-responders (n = 9) 
Age (years) 55.612.2 54.515.3 
Female (%) 81 77 
Baseline MTX Dose (mg/wk) 15.35.5 16.35.3 
DAS28 6.50.8 6.351.36 
ESR (mm/h) 44.226.4 48.837.2 
HAQ 1.750.73 1.950.7 
Pain 60.524.3 68.822.7 
Swollen Joints 25.514.3 22.118.6 
Tender Joints 26.814.1 25.516.7 
Swollen Joints (28) 15.48.3 148.9 
Tender Joints (28) 16.88.5 147.9 
CCP positive (U) 188.5252.2 76.656.2 
ACR Response 57.220.9 1015.8 
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Table 2. Polar metabolites identified and quantified by 1D 1H-NMR before and after treatment with rituximab. 
Reference values as reported in HMDB (30) were collected via NMR, unless otherwise noted. 1GC/MS 2HPLC 3HPLC-
Fluoroescence 4Ion-exchange chromatography 5DFI/MS/MS 6Unknown. ND: No data available. 
   Before After 




















2-Hydroxyvalerate ND 4.74 1.92 11.15 9.49 49.41 12.20 60.12 11.87 
3-Hydroxybutyrate 76.9±66.3 79.57 64.49 141.58 101.46 33.56 12.80 43.16 23.85 
Acetoacetate 40.6±36.5 10.11 3.87 16.27 9.73 5.75 1.48 7.00 2.85 
Acetone 54.4±29.6 15.03 7.47 18.88 12.94 16.55 6.10 16.40 4.80 
Alanine 427.2±84.4 360.34 99.62 404.54 155.44 388.91 58.24 405.61 158.20 
Asparagine 82.4±7.3 25.83 8.31 29.02 5.55 60.27 11.62 61.05 9.32 
Aspartate 20.9±6.1 70.29 27.76 86.04 46.60 51.94 14.55 67.56 16.64 
Azelate 27 (0 - 58)1 87.03 64.28 84.60 58.48 128.83 89.86 115.62 74.98 
β-Alanine 3.8±2.92 2.54 0.60 3.03 1.49 11.56 1.99 13.61 4.20 
Betaine 72±22.4 52.94 16.55 63.59 18.15 50.07 10.94 54.63 10.73 
Carnitine 45.7±11.6 25.50 6.58 28.05 11.30 37.92 7.60 36.32 4.19 
Choline 14.5±5.3 8.07 2.42 11.62 4.93 13.70 3.20 13.40 3.45 
Citrate 114.2±27 115.87 28.67 129.33 51.96 113.79 19.17 127.02 32.18 
Creatine 37.6±28.3 27.25 15.73 27.14 10.47 14.77 6.58 16.75 8.85 
Creatinine 86.6±18.8 54.18 12.62 67.49 22.70 58.11 9.18 65.59 11.56 
Dimethylamine 48.35±7.322 1.60 0.69 1.86 0.49 6.94 3.67 5.51 1.10 
Dimethylsulfone 8.8±7.3 12.98 26.99 2.40 0.73 23.24 57.14 7.36 0.70 
Formate 32.8±13.3 19.93 6.13 23.07 9.64 22.78 4.94 23.86 4.87 
Fumarate 1.5 (0 - 4)1 0.88 0.45 1.33 1.25 0.40 0.57 0.54 1.00 
Glucose 4971.3±372.8 4060.62 2338.39 3878.75 1549.05 4609.38 2155.66 5263.56 2549.87 
Glutamate 97.4±13.2 158.66 45.85 215.36 98.52 39.60 9.98 42.85 14.07 
Glutamine 510.4±118.2 513.77 136.99 535.51 156.40 376.05 57.24 396.41 97.03 
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Table 2, continued. 
   Before After 




















Glycerol 431.6±100.4 73.64 18.02 97.32 45.11 104.56 95.48 94.08 39.17 
Glycine 325.4±126.8 241.62 75.73 313.43 71.69 266.35 55.89 298.21 46.56 
Hypoxanthine 34.2±10.3 13.42 5.10 21.15 21.03 11.37 4.90 13.33 4.75 
Isoleucine 60.7±18.6 57.16 21.40 61.55 12.57 64.19 16.29 59.27 19.38 
Lactate 1489.4±371.2 3600.75 3385.26 4101.73 2338.40 2172.43 675.38 3316.75 1387.23 
Leucine 98.7±11.5 140.86 44.16 165.52 36.06 138.42 30.67 135.97 27.56 
Lysine 178.6±58.2 137.43 34.31 133.63 38.50 125.45 21.36 126.06 29.17 
Methionine 29.8±6.3 19.37 5.36 21.19 7.93 35.32 6.19 35.76 5.01 
Methylmalonate 0.187±0.0843 20.07 15.16 27.40 12.46 11.67 2.90 13.38 6.14 
Methylsuccinate ND 12.70 3.24 13.73 3.59 4.17 1.15 4.03 0.67 
O-acetylcarnitine 5.476±2.1475 3.92 1.14 4.79 1.97 3.50 0.78 4.14 0.92 
Ornithine 66.9±15.3 46.38 17.91 58.77 33.95 52.20 11.01 56.31 23.86 
Oxoisocaproate 28 (0 - 58)1 8.76 2.67 8.92 3.47 13.07 2.78 14.02 2.38 
Pantothenate 4.91±0.386 2.32 0.56 2.85 1.04 19.93 4.97 24.41 5.01 
Phenylalanine 78.1±20.5 60.88 20.01 83.00 21.66 60.14 14.63 58.79 11.70 
Propylene glycol 22.3±3.3 176.07 129.63 197.27 133.84 205.90 139.91 173.06 100.80 
Pyruvate 34.5±25.2 60.52 28.81 83.40 50.28 46.13 17.31 78.89 44.55 
Serine 159.8±26.6 153.98 35.48 182.14 51.03 138.51 20.37 152.02 37.89 
Succinate 23.5±16.01 8.01 3.83 12.88 6.11 10.82 2.02 14.46 1.44 
Taurine 55±134 238.77 54.21 279.25 54.72 120.23 13.56 140.44 21.89 
Threonine 127.7±41 202.79 219.76 514.50 513.37 118.09 14.03 119.12 22.71 
Trimethylamine 0.418±0.1241 0.85 0.50 1.22 0.76 1.84 0.98 2.18 1.28 
Tyrosine 54.5±9.7 56.67 16.66 74.21 22.88 66.58 18.81 71.57 16.24 
Urea 6074.6±2154.2 5716.72 2124.47 6101.60 2964.36 13458.43 4387.49 12896.35 4362.01 
Valine 212.3±61.3 205.42 68.10 223.46 45.24 240.52 40.65 218.62 30.61 
Xanthine 1.27±0.782 8.01 3.01 6.06 3.56 7.08 1.83 7.22 2.69 
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Table 3. Lipid species identified as statistically significant between groups prior to 
treatment with rituximab. For simplicity, only one arrangement of each fatty acid 
combination is given. Alternative fatty acid combinations are indicated where 
appropriate. O: alkyl ether linkage, P: alkenyl ether linkage 
Lipid p-value 







PG(17:0/21:0)/(22:0/16:0)/(19:0/19:0)/(20:0/18:0)   0.031176595 
TG(17:2/17:2/18:3)/(16:1/18:3/18:3) 0.037364237 








Table 4. Lipid species identified as statistically significant between groups following 
treatment with rituximab. For simplicity, only one arrangement of each fatty acid 
combination is given. Alternative fatty acid combinations are indicated where 





























Axillarenic acid/Tetracosanedioic acid 0.041115069 
beta-hydroarchaetidylglycerol 0.042645449 









Table 5. Abundance of glycerophospholipid classes in responders relative to non-
responders before and after treatment with rituximab. N/S: Not Significant, ↑ 
Upregulated in responders, ↓ Downregulated responders. 
Before Treatment Responders  After Treatment Responders 
PA N/S  PA ↑ 
PC ↑  PC ↑ 
O/P-PC N/S  O/P-PC ↓ 
PE N/S  PE ↓ 
O/P-PE ↑  O/P-PE N/S 
PG ↓  PG ↓ 
O/P-PG N/S  O/P-PG ↑ 
PI ↑  PI N/S 
O/P-PI ↓  O/P-PI ↓ 
PS ↓  PS ↑ 
O/P-PS ↓  O/P-PS ↓ 
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Table 6. Comparison of statistically significant polar metabolites within clinical 
response groups. Responders and non-responders have several shared significant 
metabolites (shown in bold) when they are compared to themselves at baseline and 6 
months. These common metabolites may be the result of effective B cell ablation by 
rituximab that is independent of clinical response. 
Responders Non-responders 
Metabolite p-value Metabolite p-value 
β-Alanine 8.47E-15 Dimethylsulfone 1.56E-09 
2-Hydroxyvalerate 5.13E-13 Pantothenate 4.54E-09 
Pantothenate 9.31E-13 2-Hydroxyvalerate 2.63E-07 
Glutamate 1.86E-09 Dimethylamine 3.64E-07 
Methylsuccinate 2.75E-09 Asparagine 5.96E-07 
Asparagine 3.14E-09 β-Alanine 5.56E-06 
Taurine 5.19E-08 Methylsuccinate 6.28E-06 
Methionine 1.62E-07 Taurine 1.98E-05 
Urea 3.67E-06 Glutamate 0.00044 
Dimethylamine 1.51E-05 Methionine 0.00084 
Choline 2.30E-05 Urea 0.00231 
Carnitine 0.00012 Oxoisocaproate 0.00508 
Oxoisocaproate 0.00037 Methylmalonate 0.01671 
Acetoacetate 0.00082 Phenylalanine 0.01874 
Glutamine 0.00251 3-Hydroxybutyrate 0.02571 
Trimethylamine 0.00261 Acetoacetate 0.02931 
Creatine 0.01375     
3-Hydroxybutyrate 0.01837     
Fumarate 0.02325     
Succinate 0.02662     




Despite the obvious impact of biologic agents, most studies still suggest that remission 
with biologic therapy is not common (40). If remission is the goal, then clearly this has not 
been uniformly achieved with the current biologic agents. There could be a number of 
reasons for this, including initiation of therapy too late in the course of disease, insufficient 
length of therapy, or inappropriate biological therapy. Improvement in diagnosis, treatment 
selection, and disease monitoring can be achieved with identification of appropriate 
biomarkers. 
“Biomarkers are defined as anatomical, physiological, biochemical, molecular 
parameters or imaging features that can be used to refine diagnosis, measure the progress 
of diseases, or predict and monitor the effects of treatment” (11). When considering 
translation into clinical practice, ideal biomarkers should be minimally invasive, readily 
accessible, and compatible with common instrumentation. Thus, biomarkers measured in 
biofluids, such as blood, are preferable to those found in tissue biopsies (11, 41). Blood 
and urine are more suitable for RA in particular, not only because of their low invasiveness, 
but also because of their abundance, since early stage RA involves mostly small joints, 
where there is very little tissue or synovial fluid to sample (11). 
Biomarkers can be separated into three major categories: diagnostic, prognostic, and 
predictive. Predictive biomarkers are those associated with a therapeutic response (11). 
These biomarkers have the potential to allow the selection of an optimal drug for a 
particular patient. More importantly, they may represent an essential step in patient 
screening that would notably allow personalized medicine models to be developed, 
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tailoring therapy to the individual, shortening time from onset to effective treatment, 
improving cost and risk-benefit ratios of drugs, and ultimately achieving high response rate 
with minimal toxicity. Currently, predictive biomarkers that would separate RA patient 
populations with respect to their outcome in response to a particular therapy is an unmet 
need (4, 7). 
Several approaches have been tried to address this issue. So far, neither genetic, 
mRNA, nor protein levels in blood have successfully identified any good biomarker (42). 
For instance, simple measures of circulating TNF or IL-1 could not be used to predict 
response to TNF inhibitors (43). Furthermore, conflicting evidence has failed to provide a 
consistent genetic marker predictive for treatment response to TNF inhibitors. Analysis of 
mRNA expression is an emerging field in the identification of predictive biomarkers and, 
consequently, there have been few studies in this area to date. However, an analysis of TNF 
mRNA expression in whole-blood samples before and after treatment with infliximab 
found no significant difference between responders and non-responders (42). Proteomic 
studies to provide protein biomarkers have several advantages over studies of single 
candidate genes and yield more information than gained from genome or transcriptome 
analysis alone. Several of the proteins involved in cartilage turnover and bone resorption 
have been shown to be good candidates as prognostic biomarkers although many of the 
analyses into their potential as predictive biomarkers of response are limited by small 
sample sizes (44). Consequently, no robust protein biomarkers have yet been confirmed as 
predicting response to TNF inhibitors or other drugs. 
 35 
Given the complexity and heterogeneous nature of RA, it is unlikely that a single 
cytokine or biomarker may provide sufficient discrimination between patients who will or 
will not respond to a given drug (11). Global biomarker signatures may represent more 
appropriate approach for improving RA patient treatment protocols and outcomes. Unlike 
genes and proteins, whose functions are subject to epigenetic regulation and post-
translational modifications, metabolites serve as direct signatures of biochemical activity 
and may be easier to correlate with phenotype (45). The fundamental rationale in 
metabolomics is that perturbations caused by a disease in a biological system will lead to 
correlated changes in certain metabolite concentrations (46). Therefore, metabolite patterns 
and pathway changes represent the final response of biological systems to disease status or 
in response to a medical or external intervention (45). NMR and/or MS can delineate 
patterns of changes and biomarkers that are highly discriminatory for the observed disease 
or intervention (10). A small number of metabolomics studies have been focused on 
identifying metabolites associated with rheumatic diseases, primarily for diagnostic 
purposes (21-23), but even fewer have attempted to predict response to treatment (9). 
Here we showed that both polar and apolar metabolite profiles are significantly 
different between RA patients who were classified as either responders or non-responders 
according to their ACR20 scores following treatment with rituximab. Prior to rituximab 
administration, 24 unique metabolites achieved p-values of less than 0.05 between patients 
who would later be categorized and responders and non-responders. When mapped into 
metabolic pathways, it becomes clear that metabolites involved in glycerophospholipid, 
amino acid, and energy metabolism are all important differentially regulated pathways. 
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Furthermore, the metabolic signatures before and after treatment were unique to each time 
point and treatment group. Following rituximab therapy, there were even greater 
differences between responders and non-responders, with 43 metabolites achieving a p-
value of 0.05 or less. Interestingly, many trends between responders and non-responders 
were ablated and, in some cases, reversed following treatment. This is likely due to the fact 
that while both groups experienced loss of circulating B-cells, there is still an obvious 
discrepancy in metabolic response to rituximab as is indicated by clinical outcomes. Due 
to the indiscriminate depletion of circulating B-cells, some changes were observed in both 
groups following treatment. However, these similarities did not obscure or inhibit detection 
of additional differences that cannot be attributed to the effect of rituximab on B cells alone 
and therefore represent the underlying metabolic differences between responders and non-
responders. 
While these findings are certainly promising, more studies are needed to investigate 
the relationship between metabolic dysregulation and RA. In particular, there is a need for 
biomarkers, or more accurately, metabolic signatures for diagnosis, prognosis, and 
especially predictive models for enhancing therapeutic protocols. Here we evaluated a 
relatively small number of patients. Our findings should be validated with a large, 
independent group of individuals to ensure accuracy and consistency between populations. 
Furthermore, this study was limited in that it assessed response to a single drug. Additional 
studies involving anti-B cell, anti T-cell, anti-IL6, and anti-TNF biological treatments 
should be evaluated simultaneously to determine whether multiple therapies can be 
successfully distinguished prior to initiation of treatment. 
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